Glenmark Life Sciences IPO Live Subscription Status

Live subscription status across each investor category and analyst recommendations
Glenmark Life Sciences IPO Subscription

Glenmark Life Sciences IPO Subscription Status: FINAL

Glenmark Life Sciences Limited, incorporated in 2001, is a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited (“Glenmark”). It is a leading developer and manufacturer of select high-value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.

Investor CategoryQuotaSubscription
Institutional (QIB)50%36.97x
Non-Insti. (HNI)15%122.54x
Retail (RII)35%14.63x
Total Subscription100%44.17x

Glenmark Life Sciences IPO Subscription: End of Day Update

DayDay 1Day 2Day 3
QIB0.00x 1.38x 36.97x
HNI0.85x 3.39x 122.54x
Retail5.16x 9.25x 14.63x
Total2.78x 5.77x 44.17x

Glenmark Life Sciences IPO Subscription: Analyst Recommendations

CHOICE BROKING – SUBSCRIBE [ Report ]

“At higher price band of Rs. 720, GLS is demanding a P/E valuation of 25.1x (to its restated FY21 EPS of Rs. 28.7), which is at discount to the peer average of 37.5x. However, based on the forecasted FY24E earnings, the demanded valuation comes out to be 11.4x, which seems to be attractive for a company generating a RoE of around 20%”

Marwadi Financial Services – SUBSCRIBE

“Considering the FY21 adjusted EPS of Rs 28.69 on post issue basis, the upper price band implies a P/E of 25.09 with a market-cap of Rs 8,822 crore, while its peers namely Divi’s Laboratories, Laurus Labs and Shilpa Medicare are trading at a P/E of 64.0, 36.1 and 36.5, respectively,”

ICICI SECURITIES – SUBSCRIBE

“Glenmark Life has a good performance execution and clean regulatory track record. The growth momentum also has a strong undercurrent of global API industry growth,”

SUBSCRIBE – Anand Rathi, Geojit Financial Services, Hem Securities, Marwadi, Religare Broking

Glenmark Life Sciences IPO Subscription: Key IPO Details

TypeValue
Issue Size₹1,513.6 Cr
Open Date27/07/2021
Close Date29/07/2021
Face Value₹2/- per Equity Share
IPO Price₹695 – ₹720
Lot Size20 shares
LotsMin 1 – Max 13

Glenmark Life Sciences IPO Subscription: Financials

201920202021
Revenue from Ops₹886.42 Cr₹1537.31 Cr₹1885.17 Cr
Profit before Excep*₹228.30 Cr₹421.07 Cr₹470.94 Cr
Profit after Tax195.59 Cr₹313.10 Cr₹351.58 Cr
EPS (Basic)24.6429.0432.61
*Tax and Exceptional Items
As of March 2020EPS (Avg*)P/E (Floor)P/E (Cap)
Based on basic EPS30.0923.1023.93
* Weighted Average for last 3 years

Comparison with listed industry peers

CompanyP/E (Cap)
Glenmark Life Sciences23.93
Highest (Divis Lab.)63.65
Lowest (Aarti Drugs)24.28
Sector Avg36.74

Glenmark Life Sciences IPO Subscription – FAQs

1. How to apply for Glenmark Life Sciences IPO in the Retail Category?

A: An investor in the retail category may either apply through the UPI process via DEMAT account or the ASBA process via bank account

2. How to apply for Glenmark Life Sciences in HNI Category?

A: An investor can apply in the HNI category only through the ASBA process via bank account

3. Where can I find the Red Herring Prospectus (RHP) details?

A: You can visit the NSE or SEBI website for these details. Alternately you can click here: RHP

Leave a Reply

fourteen + thirteen =

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.